122 related articles for article (PubMed ID: 36629283)
1. Immune-Hot tumor features associated with recurrence in early-stage ovarian clear cell carcinoma.
Huang RY; Huang KJ; Chen KC; Hsiao SM; Tan TZ; Wu CJ; Hsu C; Chang WC; Pan CY; Sheu BC; Wei LH
Int J Cancer; 2023 May; 152(10):2174-2185. PubMed ID: 36629283
[TBL] [Abstract][Full Text] [Related]
2. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.
Oliver KE; Brady WE; Birrer M; Gershenson DM; Fleming G; Copeland LJ; Tewari K; Argenta PA; Mannel RS; Secord AA; Stephan JM; Mutch DG; Stehman FB; Muggia FM; Rose PG; Armstrong DK; Bookman MA; Burger RA; Farley JH
Gynecol Oncol; 2017 Nov; 147(2):243-249. PubMed ID: 28807367
[TBL] [Abstract][Full Text] [Related]
3. Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma - A multi-institutional cohort.
Prendergast EN; Holzapfel M; Mueller JJ; Leitao MM; Gunderson CC; Moore KN; Erickson BK; Leath CA; Diaz Moore ES; Cohen JG; Walsh CS
Gynecol Oncol; 2017 Feb; 144(2):274-278. PubMed ID: 27979319
[TBL] [Abstract][Full Text] [Related]
4. Impact of the number of cycles of platinum-based chemotherapy for early stage ovarian clear cell carcinoma on survival: a retrospective study.
Gao Y
BMC Womens Health; 2023 May; 23(1):262. PubMed ID: 37189098
[TBL] [Abstract][Full Text] [Related]
5. Effect of Chemotherapy, Laparoscopy, and Cytology on Stage IC Ovarian Clear Cell Carcinoma: A Long-Term, Single-Center Study.
Chang HT; Chiu ML; Wang TY; Chen TC; Chang CL; Su TH; Wang KG; Wang KL; Yang YC; Chen JR
Int J Environ Res Public Health; 2020 Jan; 17(2):. PubMed ID: 31940991
[TBL] [Abstract][Full Text] [Related]
6. Is the presence of endometriosis associated with a survival benefit in pure ovarian clear cell carcinoma?
Sahin H; Sari ME; Cuylan ZF; Haberal AN; Sirvan L; Coban G; Yalcin I; Güngör T; Celik H; Meydanli MM; Ayhan A
Arch Gynecol Obstet; 2018 Apr; 297(4):1005-1013. PubMed ID: 29383437
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma.
Zhu J; Wen H; Bi R; Wu Y; Wu X
J Gynecol Oncol; 2017 Nov; 28(6):e77. PubMed ID: 29027395
[TBL] [Abstract][Full Text] [Related]
8. Ovarian clear cell carcinoma, outcomes by stage: the MSK experience.
Shu CA; Zhou Q; Jotwani AR; Iasonos A; Leitao MM; Konner JA; Aghajanian CA
Gynecol Oncol; 2015 Nov; 139(2):236-41. PubMed ID: 26404183
[TBL] [Abstract][Full Text] [Related]
9. Endometriosis does not confer improved prognosis in ovarian clear cell carcinoma: a retrospective study at a single institute.
Zhao T; Shao Y; Liu Y; Wang X; Guan L; Lu Y
J Ovarian Res; 2018 Jun; 11(1):53. PubMed ID: 29941051
[TBL] [Abstract][Full Text] [Related]
10. Prognostic determinants in patients with uterine and ovarian clear carcinoma.
Rauh-Hain JA; Winograd D; Growdon WB; Schorge JO; Goodman AK; Boruta DM; Berkowitz RS; Horowitz NS; Del Carmen MG
Gynecol Oncol; 2012 May; 125(2):376-80. PubMed ID: 22366593
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a Surveillance, Epidemiology, and End Results Cohort Study, 2000-2013.
Oseledchyk A; Leitao MM; Konner J; O'Cearbhaill RE; Zamarin D; Sonoda Y; Gardner GJ; Long Roche K; Aghajanian CA; Grisham RN; Brown CL; Snyder A; Chi DS; Soslow RA; Abu-Rustum NR; Zivanovic O
Ann Oncol; 2017 Dec; 28(12):2985-2993. PubMed ID: 28950307
[TBL] [Abstract][Full Text] [Related]
12. Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype.
Takenaka M; Köbel M; Garsed DW; Fereday S; Pandey A; Etemadmoghadam D; Hendley J; Kawabata A; Noguchi D; Yanaihara N; Takahashi H; Kiyokawa T; Ikegami M; Takano H; Isonishi S; Ochiai K; Traficante N; Gadipally S; Semple T; Vassiliadis D; Amarasinghe K; Li J; Mir Arnau G; Okamoto A; Friedlander M; Bowtell DDL;
Clin Cancer Res; 2019 Jul; 25(13):3962-3973. PubMed ID: 30967419
[TBL] [Abstract][Full Text] [Related]
13. Venous thromboembolism during primary treatment of ovarian clear cell carcinoma is associated with decreased survival.
Diaz ES; Walts AE; Karlan BY; Walsh CS
Gynecol Oncol; 2013 Dec; 131(3):541-5. PubMed ID: 24041880
[TBL] [Abstract][Full Text] [Related]
14. Serum D-dimer, albumin and systemic inflammatory response markers in ovarian clear cell carcinoma and their prognostic implications.
Chen W; Zhong S; Shan B; Zhou S; Wu X; Yang H; Ye S
J Ovarian Res; 2020 Aug; 13(1):89. PubMed ID: 32771026
[TBL] [Abstract][Full Text] [Related]
15. Ovarian clear cell carcinoma with or without endometriosis origin in a single institution cohort.
Sun M; Jiang W
Discov Oncol; 2023 Apr; 14(1):39. PubMed ID: 37004660
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of neutrophil-to-lymphocyte ratio in early-stage ovarian clear-cell carcinoma.
Yoshida K; Yoshikawa N; Shirakawa A; Niimi K; Suzuki S; Kajiyama H; Kikkawa F
J Gynecol Oncol; 2019 Nov; 30(6):e85. PubMed ID: 31576683
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological and survival characteristic of mismatch repair status in ovarian clear cell carcinoma.
Zhu J; Ke G; Bi R; Wu X
J Surg Oncol; 2020 Sep; 122(3):538-546. PubMed ID: 32396667
[TBL] [Abstract][Full Text] [Related]
18. Management and clinical outcomes of patients with recurrent/progressive ovarian clear cell carcinoma.
Huang HJ; Yang LY; Tung HJ; Ku FC; Wu RC; Tang YH; Chang WY; Jung SM; Wang CC; Lin CT; Liu FY; Lin G; Chen MY; Chou HH; Chang TC; Chao A; Lai CH
J Formos Med Assoc; 2020 Apr; 119(4):793-804. PubMed ID: 31818713
[TBL] [Abstract][Full Text] [Related]
19. Analysis of gene expression signatures identifies prognostic and functionally distinct ovarian clear cell carcinoma subtypes.
Tan TZ; Ye J; Yee CV; Lim D; Ngoi NYL; Tan DSP; Huang RY
EBioMedicine; 2019 Dec; 50():203-210. PubMed ID: 31761620
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of interleukin-6 expression in stage I ovarian clear cell carcinoma.
Kawabata A; Yanaihara N; Nagata C; Saito M; Noguchi D; Takenaka M; Iida Y; Takano H; Yamada K; Iwamoto M; Kiyokawa T; Okamoto A
Gynecol Oncol; 2017 Sep; 146(3):609-614. PubMed ID: 28673661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
